Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 16Active not recruiting 11Suspended 2Completed 1Available 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Neoplasm Metastasis 5Colorectal Neoplasms 5Breast Neoplasms 5Neoplasms 4Multiple Myeloma 4Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumor 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Mesothelioma, Malignant 2Melanoma 2Lymphoma, T-Cell 2Lung Neoplasms 2Immunoblastic Lymphadenopathy 2Glioblastoma 2Carcinoma, Renal Cell 2Carcinoma 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Spinal Diseases 1Spinal Cord Neoplasms 1Solid Tumors 1

Interventions

Specimen Handling 2trastuzumab deruxtecan 1fludarabine phosphate 1X-Rays 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Osteosarcoma × 30 days × Clear all
NCT04539366 2026-05-13

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

National Cancer Institute (NCI)

Phase 1 Suspended
67 enrolled
CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT04616560 2026-05-13

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Suspended
77 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡